Journal
FRONTIERS IN PHARMACOLOGY
Volume 13, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2022.893422
Keywords
GPCR; Alzheimer's disease; neurodegenerative disease; neuroinflammation; G protein coupled receptors; drug discovery
Categories
Ask authors/readers for more resources
This article discusses the potential of mGlu(5) as a therapeutic target for neurodegenerative diseases and its role in neuroinflammatory responses, providing new possibilities for the treatment of neurodegenerative diseases.
The type 5 metabotropic glutamate receptor, mGlu(5), has been proposed as a potential therapeutic target for the treatment of several neurodegenerative diseases. In preclinical neurodegenerative disease models, novel allosteric modulators have been shown to improve cognitive performance and reduce disease-related pathology. A common pathological hallmark of neurodegenerative diseases is a chronic neuroinflammatory response, involving glial cells such as astrocytes and microglia. Since mGlu(5) is expressed in astrocytes, targeting this receptor could provide a potential mechanism by which neuroinflammatory processes in neurodegenerative disease may be modulated. This review will discuss current evidence that highlights the potential of mGlu(5) allosteric modulators to treat neurodegenerative diseases, including Alzheimer's disease, Huntington's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Furthermore, this review will explore the role of mGlu(5) in neuroinflammatory responses, and the potential for this G protein-coupled receptor to modulate neuroinflammation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available